Peptides have emerged as a promising class of therapeutics due to their high specificity, potency, and relatively low toxicity. However, their clinical application has been limited by issues such as enzymatic degradation, poor membrane permeability, and short half-life. Cyclization—a process that covalently links two parts of a peptide chain—has been widely employed to overcome these challenges. Traditionally, cyclization is achieved via amide bond formation, but recent advances in chemical biology have introduced a diverse range of non-amide strategies, particularly those grounded in click chemistry.
Click chemistry describes a class of reactions that are modular, high-yielding, and bioorthogonal. These reactions have transformed the landscape of peptide chemistry by enabling efficient, selective, and rapid cyclization under mild conditions. Beyond click reactions, other non-amide approaches such as Michael addition and thioether formation also contribute significantly to the design of stable, functional cyclic peptides. This article explores the rationale, methods, and applications of non-amide peptide cyclization, with a particular focus on click-based reactions such as CuAAC (copper-catalyzed azide-alkyne cycloaddition), as well as alternative strategies like thiol-ene cyclization and Michael-type additions.
Cyclic peptides have garnered growing attention in both drug discovery and biochemical research, owing to their unique structural advantages. By locking linear peptides into ring-like conformations, cyclization enhances a range of properties—including metabolic stability, target specificity, and resistance to enzymatic breakdown. Traditionally, these cyclic structures are formed through amide bond linkages, such as head-to-tail cyclization or side-chain cross-linking. Yet, with the advent of modern synthetic techniques, a new wave of non-amide cyclization methods is expanding the possibilities for peptide design.
Unlike classical approaches, non-amide cyclization strategies forge covalent bonds between atoms outside the peptide backbone. These include triazole rings, thioether linkages, and even direct carbon–carbon connections—often constructed through reactions that are orthogonal to biological systems. Such methods bring a new level of architectural freedom, enabling chemists to fine-tune peptide function, apply bioorthogonal labeling, and access structures previously out of reach using traditional methods. Among these innovations, click chemistry has stood out as a particularly robust and versatile approach. Its high chemoselectivity, biocompatible conditions, and reliable yields make it a powerful tool for crafting stable and functional cyclic peptides with precision. In this section, we explore why alternative linkages are used, the structural and pharmacological benefits they bring, and the main types of click-based reactions employed in modern peptide science.
Although amide bond cyclization is widely used and well-understood, it comes with several limitations. Most notably, amide bonds are substrates for proteolytic enzymes, which can lead to rapid degradation of linear or cyclic peptides in biological environments. Furthermore, forming amide bonds requires precise control over reaction conditions to avoid epimerization and side reactions, especially in complex or longer peptide sequences.
Non-amide linkages offer several distinct advantages. First, they introduce chemically unnatural features into the peptide scaffold, which are often unrecognizable by proteases. This significantly enhances the metabolic stability of the peptide in vivo. Second, these linkages can be formed using a broader range of chemistries, such as copper-catalyzed azide-alkyne cycloaddition (CuAAC), thiol-ene reactions, or Michael-type additions. These reactions are often orthogonal to the functional groups present in peptides, allowing for selective modification without disturbing the rest of the molecule. Moreover, non-amide cyclization allows for the use of unnatural amino acids or synthetic building blocks, enabling fine-tuning of physicochemical properties such as solubility, hydrophobicity, or rigidity. This expanded chemical repertoire is especially valuable in drug design, where even slight modifications can drastically affect target binding, pharmacokinetics, and bioavailability.
One of the major drivers for using non-amide cyclization strategies is the structural diversity and enhanced pharmacological performance they offer. By moving beyond traditional peptide bonds, researchers can engineer cyclic structures that are more rigid, conformationally constrained, and functionally optimized for specific targets.
Structural Benefits
Non-amide linkages, such as triazoles or thioethers, often introduce a degree of conformational constraint that cannot be easily achieved through amide bonds alone. For example, the 1,2,3-triazole ring formed through CuAAC mimics the size and hydrogen bonding potential of an amide bond but locks the peptide into a more defined spatial arrangement. This can improve target affinity by reducing the entropic penalty upon binding and maintaining a preorganized active conformation. Additionally, these linkages can bridge side chains or termini in ways that traditional peptide chemistry cannot, enabling the creation of macrocycles with tailored loop sizes, topologies, and orientations. Such diversity is crucial in designing molecules that can bind to shallow or extended surfaces like those found in protein-protein interactions (PPIs).
Pharmacological Advantages
Non-amide cyclization also leads to peptides with superior pharmacological profiles. Their enhanced proteolytic resistance means longer circulation times and improved bioavailability, making them more attractive for systemic administration. Furthermore, some non-amide linkages are more hydrophobic or lipophilic, which can improve membrane permeability—a key limitation for many therapeutic peptides. Incorporating non-canonical chemical moieties also allows for reduced immunogenicity and increased metabolic stability. This is particularly useful in peptide-based vaccines, drug carriers, or targeting ligands, where sustained bioactivity and low off-target effects are essential.
Among non-amide cyclization methods, click chemistry stands out for its efficiency, selectivity, and compatibility with biological systems. The term "click chemistry," originally defined by Sharpless and colleagues, refers to a set of reactions that are modular, high-yielding, and require minimal purification. They also proceed under mild conditions and often tolerate aqueous environments, making them ideal for peptide modification.
Here are the most commonly used click-based reactions for peptide cyclization:
Copper-catalyzed azide-alkyne cycloaddition (CuAAC) has become one of the most influential chemical tools in modern peptide science, particularly for macrocyclization, conjugation, and labeling. As the prototypical example of "click chemistry," CuAAC offers a highly efficient, selective, and modular method for forming triazole linkages between azide- and alkyne-containing groups. These unique chemical properties, combined with the reaction's functional group tolerance and compatibility with aqueous environments, make CuAAC an ideal approach for peptide cyclization and biomedical applications.
Copper-catalyzed azide-alkyne cycloaddition (CuAAC) has become a widely adopted tool in peptide chemistry due to its efficiency, selectivity, and simplicity. At the heart of this reaction are two key functional groups: an azide and a terminal alkyne. These components, when combined in the presence of a copper(I) catalyst, undergo a cycloaddition reaction to form a 1,4-disubstituted 1,2,3-triazole ring. This triazole linkage is highly stable, mimics the geometry of an amide bond to some extent, and is resistant to enzymatic degradation—making it ideal for peptide macrocyclization and labeling applications.
The copper(I) catalyst is typically generated in situ by reducing copper(II) sulfate (CuSO4) with a reductant such as sodium ascorbate. In some cases, copper(I) halides like CuI or CuBr are used directly. However, to improve solubility, minimize copper-induced peptide oxidation, and stabilize the catalytic species, ligands such as TBTA (tris(benzyltriazolylmethyl)amine) or THPTA (tris(hydroxypropyltriazolylmethyl)amine) are frequently included in the reaction. These ligands help modulate the reactivity and bio-compatibility of the copper catalyst. The reaction conditions are typically mild and aqueous, often using water or water-organic solvent mixtures (like tert-butanol or DMF) at room temperature. This makes CuAAC particularly attractive for modifying sensitive biomolecules such as peptides, which can degrade under harsh conditions. The reaction usually proceeds to completion in a few hours and does not require extensive purification, making it suitable for both solution-phase and solid-phase peptide synthesis.
One of the defining advantages of CuAAC is that it exemplifies the principles of bioorthogonal chemistry. Bioorthogonal reactions are chemical transformations that proceed efficiently and selectively in complex biological environments without interfering with natural biochemical processes. CuAAC fulfills this criterion because the reactive partners—azides and alkynes—are not found in biological systems, and therefore react selectively with each other without affecting other functional groups within proteins or nucleic acids.
This chemical orthogonality allows CuAAC to be performed in the presence of a wide variety of biomolecules without undesired side reactions. Furthermore, the reaction conditions are compatible with aqueous media, near-neutral pH, and physiological temperatures, which ensures the integrity of sensitive peptide structures during the cyclization or conjugation process. The triazole product is not only chemically stable but also inert in most biological contexts, resisting hydrolysis and enzymatic cleavage. Despite its advantages, one limitation of CuAAC in live-cell or in vivo settings is the toxicity of copper ions. Free Cu(I) can catalyze the generation of reactive oxygen species, leading to oxidative damage. This concern has led to the development of copper-free click reactions, such as strain-promoted azide-alkyne cycloaddition (SPAAC), for in vivo applications. Nonetheless, CuAAC remains a cornerstone technique in chemical biology and peptide science, particularly for in vitro applications and synthesis.
CuAAC-based peptide cyclization and conjugation have found broad applications in imaging, targeting, and therapeutic development. The ability to form stable, site-specific triazole linkages makes CuAAC an ideal platform for constructing bioconjugates with enhanced pharmacokinetics and target specificity. In molecular imaging, for instance, cyclic peptides functionalized with CuAAC-reactive handles can be conjugated to fluorescent dyes or radiolabels, creating probes for real-time tracking of biological processes. These conjugates can be used in optical imaging, positron emission tomography (PET), or single-photon emission computed tomography (SPECT) to visualize tumor-specific markers or track drug distribution.
Beyond imaging, CuAAC is frequently used to generate high-affinity ligands for targeted drug delivery. Peptides with known receptor specificity—such as those targeting integrins, somatostatin receptors, or growth factor receptors—can be cyclized and modified using CuAAC to improve their stability and enhance their binding affinity. These cyclic peptides can then be conjugated to nanoparticles, liposomes, or drug carriers, enabling precise delivery of therapeutic agents to disease-relevant tissues while minimizing systemic toxicity. In the realm of chemical biology, CuAAC has facilitated the development of peptide-based probes for target identification, activity-based protein profiling, and pull-down assays. Peptides modified with biotin or affinity tags through CuAAC can be used to isolate interacting proteins or map binding sites, aiding in drug discovery and mechanistic studies. The modularity of CuAAC also makes it particularly suitable for library construction and screening, allowing rapid synthesis of diverse macrocyclic scaffolds for high-throughput evaluation.
Beyond click chemistry, a range of alternative non-amide cyclization methods have been developed to expand the chemical versatility of cyclic peptides. Among these, Michael addition and thioether bonding represent particularly valuable strategies for introducing stable, non-hydrolyzable linkages into peptide scaffolds. These approaches take advantage of nucleophilic and electrophilic functional groups either naturally present in amino acid side chains or incorporated synthetically. Their utility lies in the ability to produce chemically diverse macrocyclic structures under mild conditions, often without the need for metal catalysts. While not as universally applied as copper-catalyzed click chemistry, Michael-type additions and thioether cyclizations provide useful tools for designing protease-resistant, conformationally constrained peptide therapeutics.
Thiol-ene cyclization is a radical-mediated reaction in which a thiol group, commonly derived from a cysteine residue, reacts with an alkene to form a thioether linkage. This reaction proceeds through a free radical mechanism, typically initiated by ultraviolet (UV) light or thermal initiators such as azobisisobutyronitrile (AIBN). The formation of the thioether bond is highly efficient and irreversible, resulting in a stable, non-reducible linkage ideal for macrocyclization. The success of thiol-ene cyclization depends heavily on the reaction conditions. Oxygen must be minimized or eliminated, as it can quench radical species and inhibit the reaction. The pH should remain neutral to slightly basic, since overly acidic environments may suppress the nucleophilicity of the thiol group. Additionally, the concentration of the peptide and radical initiator must be optimized to promote intramolecular (rather than intermolecular) cyclization, especially when the reactive groups are positioned on side chains rather than termini.
Peptide cyclization via Michael addition or thioether formation often relies on side chains that bear nucleophilic or electrophilic functional groups. Naturally occurring amino acids provide several such handles. Cysteine is perhaps the most commonly used residue in this context, as its thiol group readily participates in both nucleophilic Michael-type additions and thiol-ene reactions. Under appropriate conditions, the cysteine thiol can attack an activated alkene, such as a maleimide, acrylate, or dehydroalanine derivative, to form a stable carbon-sulfur bond.
Lysine and ornithine residues offer primary amines on their side chains, which can act as nucleophiles in certain conjugate addition reactions. Similarly, the carboxylate groups of aspartic acid and glutamic acid can be modified to function as electrophiles, though they are more commonly used in traditional amide cyclizations. Unnatural amino acids further expand the range of reactive groups available. For instance, residues bearing vinyl or allyl functionalities can be incorporated to serve as electrophilic partners in radical cyclizations or Michael-type reactions. The location of these reactive side chains within the peptide sequence significantly influences the efficiency and outcome of cyclization. Side-chain-to-side-chain cyclization generally requires precise spatial orientation to ensure favorable intramolecular reactions. Incorporating spacer residues or adopting defined secondary structures, such as α-helices or β-turns, can help bring reactive groups into proximity. Careful sequence design is essential to prevent side reactions, especially when multiple nucleophilic or electrophilic residues are present. Solid-phase synthesis platforms facilitate this precision by allowing selective functional group protection and deprotection strategies.
Non-amide cyclization strategies such as Michael addition and thioether formation present both advantages and limitations when compared to traditional amide-based cyclization. One of the most significant benefits is the introduction of linkages that are resistant to enzymatic hydrolysis. Whereas amide bonds are readily cleaved by proteases, thioether and carbon-carbon bonds formed through non-amide strategies are often inert to enzymatic attack. This stability translates into improved pharmacokinetic profiles and prolonged biological half-life—key attributes for therapeutic peptides. Moreover, non-amide linkages frequently impose greater conformational constraints on the peptide backbone, which can enhance binding specificity and reduce entropic penalties upon target interaction. These rigid structures can better mimic biologically relevant motifs, such as β-turns or loop regions, and are often favored in the design of inhibitors for protein-protein interactions. In addition, non-amide cyclization reactions are often orthogonal to traditional peptide chemistry, allowing them to be conducted at later synthetic stages without interference from native peptide bonds.
However, these approaches also present challenges. Incorporating reactive side chains or unnatural amino acids often requires additional synthetic steps, which can increase cost and complexity. Radical-mediated reactions like thiol-ene cyclization require specialized conditions, such as UV light exposure or radical initiators, which may not be compatible with all functional groups or peptide sequences. Furthermore, the lack of naturally occurring analogs to these non-amide linkages may sometimes reduce biological recognition or induce immunogenic responses, depending on the application. From a structural standpoint, while non-amide linkages offer enhanced rigidity, they may also limit conformational flexibility, which can be detrimental if the target receptor requires adaptive binding. Finally, scale-up and purification of non-amide cyclized peptides can be more complicated, particularly when multiple reactive groups are present or when regioselectivity is difficult to control. Despite these limitations, the unique properties of Michael-type and thioether cyclization methods make them powerful complements to traditional amide cyclization. When carefully designed and appropriately applied, they provide access to peptide scaffolds with improved therapeutic potential, novel mechanisms of action, and expanded chemical diversity.
Looking for a reliable partner to help you synthesize high-purity cyclic peptides? At Creative Peptides, we specialize in custom peptide synthesis, with deep expertise in head-to-tail, side-chain, enzymatic, and non-traditional cyclization strategies.
Whether you're developing therapeutic peptides, researching structure-activity relationships, or scaling up for preclinical studies - we can support your project from design to delivery.
Contact us now to discuss your requirements and receive a free technical consultation.
Peptide Synthesis Services at Creative Peptides
